Not for human consumption

Mazdutide Peptide: Dual GLP-1/Glucagon Receptor Agonist (IBI362, LY3305677) | Research Grade

Mazdutide research peptide: ≥99% HPLC-verified purity, manufactured in LiveWell’s own Dallas cGMP facility. Mazdutide (IBI362, LY3305677) is a lipidated oxyntomodulin analog that activates both the GLP-1 and glucagon receptors, developed by Eli Lilly and Innovent, with Phase 3 GLORY-1 results in the New England Journal of Medicine and GLORY-2 in JAMA. Supplied as a 10 mg lyophilized vial for in-vitro laboratory research use only.

Coming soon: pre-orders are open now. The first production batch is in the manufacturing and QC queue. Expected ship date: to be announced. Pre-orders ship in the order received once the batch clears third-party testing and the COA is published. Your card is charged at checkout and you can cancel any time before shipment for a full refund.

CAS Number: 2259884-03-0 · Development codes: IBI362, LY3305677
Vial size: 10 mg lyophilized powder
Class: Dual GLP-1/glucagon receptor agonist, oxyntomodulin analog with C20 fatty diacid, once-weekly exposure profile in published trials
Purity: ≥99% HPLC, third-party tested, COA published on release
Shipping: USA same-day once released (orders before 2pm CT, Mon to Fri) · free over $200

Related: Retatrutide · Tirzepatide · Survodutide

For laboratory research use only. Not for human or animal consumption. Full details ↓

$ 109.99

Available on backorder

⚠️ Strictly for laboratory research use only. Not for human or animal consumption.

Quantity	Price	Discount
3-5	$ 98.99	10%
6-9	$ 93.49	15%
10+	$ 87.99	20%

Available on backorder

Add $ 200.00 to cart and get free shipping!

Description

Mazdutide: Dual GLP-1/Glucagon Receptor Agonist for Research Use

Mazdutide (IBI362, LY3305677) is a synthetic analog of oxyntomodulin, the gut hormone that naturally activates both the GLP-1 receptor and the glucagon receptor. A C20 fatty diacid side chain provides albumin binding and a once-weekly exposure profile. It was discovered by Eli Lilly and developed in Greater China by Innovent Biologics, where it became the first dual GLP-1/glucagon agonist approved anywhere (China, 2025, brand name Xinermei). Outside China it remains investigational. LiveWell supplies it as a 10 mg lyophilized vial strictly for in-vitro laboratory research use only.

Chemical Information

Name: Mazdutide (IBI362, LY3305677, OXM-3)
CAS Number: 2259884-03-0
Type: Synthetic lipidated oxyntomodulin analog (research grade)
Molecular formula: C207H317N45O65
Structure: Oxyntomodulin-based sequence with a C20 fatty diacid side chain for albumin binding
Receptor profile: Dual GLP-1 and glucagon receptor agonist
Exposure profile: once-weekly subcutaneous dosing in all published human trials
Vial size: 10 mg lyophilized powder
Purity: ≥99% (HPLC, third-party tested)

Why Researchers Study Mazdutide

1. Oxyntomodulin pharmacology. Mazdutide is the most advanced oxyntomodulin analog, making it the reference compound for research on the natural dual GLP-1/glucagon signal and how lipidation converts a short-lived gut hormone into a weekly-exposure molecule.

2. The largest dual-agonist Phase 3 dataset. GLORY-1 (NEJM, 2025), GLORY-2 (JAMA, 2026) and the DREAMS diabetes trials (Nature, 2025) give researchers dose-response, glycemic and safety data across more than 2,000 participants.

3. Comparative agonist research. Mazdutide (GLP-1/glucagon) is studied against Tirzepatide (GIP/GLP-1), Survodutide (glucagon/GLP-1 on a glucagon backbone) and Retatrutide (triple agonist) to separate receptor contributions in cell and animal models.

4. High-dose exposure research. A Lilly Phase 1 study escalated to 16 mg weekly and reported about 20% body-weight change over 20 weeks, one of the steepest dose-response curves published for the class.

Published Clinical Literature (Research Reference)

For context only. These are results from the Innovent and Eli Lilly clinical programs. These are results cited from peer-reviewed sources; they are not claims about LiveWell’s research-grade material.

Phase 2 obesity (Nat Commun, 2023): 248 participants, 24 weeks; minus 6.7% (3 mg), minus 10.4% (4.5 mg), minus 11.3% (6 mg) versus plus 1.0% placebo.
GLORY-1, Phase 3 obesity (NEJM, 2025): 610 participants, 48 weeks; minus 11.0% (4 mg) and minus 14.0% (6 mg) versus plus 0.3% placebo; GI events mild to moderate, discontinuation 0.5% to 1.5%.
GLORY-2, 9 mg (JAMA, 2026): 461 participants, 60 weeks; minus 16.65% versus minus 1.50%; 84.3% lost 5% or more; vomiting 53%, nausea 47%, diarrhea 39%.
DREAMS-1 and DREAMS-2, type 2 diabetes (Nature, 2025): HbA1c minus 1.57% to minus 2.15% versus placebo at 24 weeks, and superiority to dulaglutide 1.5 mg at 28 weeks.
Regulatory: approved in China (NMPA) in June 2025 for chronic weight management and September 2025 for type 2 diabetes as Xinermei; not approved or filed in the US or EU as of September 2026.

Storage & Handling

Store lyophilized vials refrigerated at 2 to 8°C, protected from light and heat
Reconstitute with bacteriostatic water; reconstituted material has a shorter storage window
Follow your laboratory’s standard peptide handling protocol

⚠️ Disclaimer: Mazdutide research peptide is intended strictly for laboratory research and in-vitro use only. It is not a drug, food, cosmetic, or dietary supplement. This product has not been evaluated or approved by the FDA and is not for human or veterinary use. No therapeutic, weight-management or metabolic-health claims are made or implied.

Regulatory status: Mazdutide is approved only in China (NMPA, 2025) and is an investigational compound in the United States and every other market as of September 2026. The research-grade material sold by LiveWell is not a drug product: it is not manufactured, compounded, or approved for pharmaceutical use, and is strictly for in-vitro laboratory research. Nothing on this page constitutes medical advice.

Mazdutide research reference: View the GLORY-1 Phase 3 trial on PubMed

Pre-Order Mazdutide Research Peptide: cGMP Manufactured in Dallas, TX

Qualified researchers can pre-order Mazdutide directly from the manufacturer. LiveWell Peptides produces research-grade Mazdutide in our cGMP facility in Dallas, Texas. Every vial is third-party tested to verify ≥99% HPLC purity, amino acid identity by mass spectrometry, and endotoxin limits by LAL testing, and the batch COA is published on our COA page on the day of release. Pre-orders ship in the order received (expected ship date: to be announced); once released, US orders placed before 2pm CT (Mon to Fri) ship same-day in cold-chain packaging, with free domestic shipping over $200. International shipping is available.

Why Researchers Source Mazdutide from LiveWell

Documentation, not claims. Every batch ships with a verified COA confirming identity and purity, published on our COA page rather than supplied only on request.

Four-point analytical testing. HPLC for purity, mass spectrometry for amino acid identity, and LAL testing for endotoxins, with independent third-party verification on top of in-house quality control.

US manufacturing and cold-chain logistics. Orders ship from our Dallas, Texas facility, with international shipping to Colombia, Mexico, Brazil, Argentina, Chile and Peru.

Related research compounds

Retatrutide (Triple GLP-1/GIP/Glucagon) · Tirzepatide (Dual GIP/GLP-1) · Survodutide (Dual Glucagon/GLP-1) · Semaglutide (GLP-1) · Bacteriostatic Water · Certificates of Analysis

Research literature

Selected peer-reviewed sources for research reference:

Ji L et al. (2025). Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1). N Engl J Med. PMID: 40421736
Gao L et al. (2026). Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: GLORY-2. JAMA. PMID: 42251595
Zhu D et al. (2025). Mazdutide versus placebo in Chinese adults with type 2 diabetes (DREAMS-1). Nature. PMID: 41407859
Ji L et al. (2023). A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. PMID: 38092790
Shirley M. (2025). Mazdutide: First Approval. Drugs. PMID: 41028652

References are provided for research reference only. Inclusion of literature does not constitute a recommendation, endorsement, or claim for any specific use of LiveWell Peptides products. Products are sold for laboratory and research use only and are not intended for human consumption, injection, topical application, or any other administration to the human body.

Frequently Asked Questions

What is Mazdutide?

Mazdutide (IBI362, LY3305677, CAS 2259884-03-0) is a lipidated oxyntomodulin analog that activates both the GLP-1 and glucagon receptors, discovered by Eli Lilly and developed in China by Innovent. We supply it as a 10 mg lyophilized vial strictly for in-vitro laboratory research.

How does Mazdutide differ from Tirzepatide?

Tirzepatide pairs GLP-1 with GIP. Mazdutide pairs GLP-1 with glucagon, which in the published trials is linked to added energy expenditure and liver-fat effects. No head-to-head trial has been published.

How does Mazdutide compare with Survodutide and Retatrutide?

Survodutide is also a GLP-1/glucagon dual agonist but is built on a glucagon backbone rather than oxyntomodulin. Retatrutide adds GIP as a third receptor. Comparisons across the three rely on separate trials.

What did the GLORY Phase 3 trials report?

GLORY-1 (NEJM, 2025, 610 participants, 48 weeks) reported minus 14.0% body-weight change on 6 mg versus plus 0.3% placebo. GLORY-2 (JAMA, 2026, 9 mg, 60 weeks) reported minus 16.65% versus minus 1.50%. Gastrointestinal events were the main adverse events. Cited for research reference only.

Is Mazdutide approved anywhere?

Yes, in China, where the NMPA approved it as Xinermei for chronic weight management (June 2025) and type 2 diabetes (September 2025). It is not approved in the United States or the European Union.

What purity is LiveWell Mazdutide, and is a COA included?

Every batch is third-party tested at ≥99% purity by HPLC, with mass spectrometry identity confirmation and LAL endotoxin testing. The batch Certificate of Analysis is published on our COA page the day the pre-order batch is released.

How should Mazdutide be stored and reconstituted?

Store the lyophilized vial refrigerated at 2 to 8°C, protected from light and heat. Reconstitute with bacteriostatic water; reconstituted material has a considerably shorter storage window.

How do pre-orders work, and when will it ship?

Pre-orders are charged at checkout and ship in the order received once the first batch clears third-party testing and the COA is published. You will receive tracking the day it ships. If you change your mind before shipment, contact us for a full refund.

Is Mazdutide a drug or supplement in the United States?

No. In the United States, Mazdutide is an investigational compound that has not been approved by the FDA. The research-grade material sold by LiveWell is not a drug product, dietary supplement, food or cosmetic, and it is not intended for human or animal consumption.

Péptidos de investigación disponibles con envío internacional. Mazdutida de grado de investigación fabricada en instalaciones cGMP en Dallas, Texas. Certificado de análisis incluido con cada lote. Solo para uso en investigación.

Research Use Only Disclaimer: This product is sold strictly for in vitro laboratory research. NOT for human or animal consumption. LiveWell Peptides makes no medical claims.